Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.51 |
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | RXRG | P48443 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1403550 | 0.83 | RXRA (0.59) | DAORXRARXRBRXRGMRGPRX4 | |
| SCHEMBL29989384 | 0.83 | RXRA (0.59) | DAORXRARXRBRXRGMRGPRX4 | |
| SCHEMBL585165 | 0.82 | FFAR4 (0.51) | FFAR1DAOFFAR4RXRARXRB | |
| SCHEMBL793963 | 0.80 | CYP4F2 (0.52) | FFAR1DAOFFAR4EPHX2MRGPRX4 | |
| SCHEMBL1206803 | 0.79 | FFAR1 (0.69) | FFAR1FFAR4 | |
| SCHEMBL1567847 | 0.79 | NR3C2 (0.51) | FFAR1FFAR4EPHX2 | |
| SCHEMBL30151151 | 0.79 | NR3C2 (0.51) | FFAR1FFAR4EPHX2 | |
| SCHEMBL5200292 | 0.78 | FFAR1 (0.51) | FFAR1FFAR4 | |
| SCHEMBL28741568 | 0.78 | GRIK1 (0.49) | DAOMRGPRX4 | |
| SCHEMBL22630207 | 0.77 | FFAR1 (0.56) | FFAR1FFAR4EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| EP-2627648-A1 | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| CN-103108871-A | 17a-hydroxylase/c17,20-lyase inhibitors | NOVARTIS AG | 2013-05-15 | — | — | CN | disclosed |
| CN-101568542-B | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives | ACTELION PHARMACEUTICALS LTD | 2013-03-27 | — | — | CN | disclosed |
| US-8188082-B2 | 5,6,7,8-tetrahydro-imidazo[1,5-α]pyrazine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-29 | — | — | US | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| EP-2125823-B1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-2125823-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | disclosed |
| CN-101568542-A | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-28 | — | — | CN | disclosed |
| WO-2008078291-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | HCRTR1, HCRTR2, NPY5R | FFAR1 192/4885DAO 910/4885FFAR4 191/4885 |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | FFAR1 2659/4885DAO 274/4885FFAR4 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.